Showing results (1791-1800 of 1,838) with videos related to

Sort By:
Pageof 184
Brain : a Journal of Neurology|June 18, 2014
A mitochondrial origin for frontotemporal dementia and amyotrophic lateral sclerosis through CHCHD10 involvementSylvie Bannwarth, Samira Ait-El-Mkadem, Annabelle Chaussenot, et al.
British Journal of Cancer|January 10, 2024
Autoantibodies, antigen-autoantibody complexes and antigens complement CA125 for early detection of ovarian cancerChae Young Han, Jacob S Bedia, Wei-Lei Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2022
Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III TrialJoyce F Liu, Mark F Brady, Ursula A Matulonis, et al.
Nature Communications|July 24, 2015
Observation of universal strong orbital-dependent correlation effects in iron chalcogenidesM Yi, Z-K Liu, Y Zhang, et al.
Science (New York, N.Y.)|March 8, 2014
Large-amplitude spin dynamics driven by a THz pulse in resonance with an electromagnonT Kubacka, J A Johnson, M C Hoffmann, et al.
Journal of the American Society of Nephrology : JASN|January 30, 2016
Predicted Mutation Strength of Nontruncating PKD1 Mutations Aids Genotype-Phenotype Correlations in Autosomal Dominant Polycystic Kidney DiseaseChristina M Heyer, Jamie L Sundsbak, Kaleab Z Abebe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 3, 2024
Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005Jung-Min Lee, Mark F Brady, Austin Miller, et al.
Biorxiv : the Preprint Server for Biology|May 18, 2026
IL1β/IL1R1/IRAK4 Drives Inflammatory Ovarian Cancer Seeding at the inflamed sites and Is Reversed by an IRAK4 inhibitor UR241-2John P Miller, Kyu Kwang Kim, Cameron Wa Snyder, et al.
Gynecologic Oncology|May 13, 2022
Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 studyRoisin E O'Cearbhaill, Jose-Alejandro Pérez-Fidalgo, Bradley J Monk, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2011
Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter studyWilliam J Irvin, Christine M Walko, Karen E Weck, et al.
Pageof 184